Strategic Acquisition Evoke Neuroscience has recently been acquired by Firefly Neuroscience, signaling integration into a broader cognitive electrophysiology platform and potential access to Firefly's broader distribution, resources, and cross-customer base for accelerated market penetration.

Clinical Adoption The FDA-cleared Evoke EEG System provides objective biomarkers via event-related potentials, enabling earlier detection, differential diagnosis, and treatment tracking, which can be positioned to neurology, psychiatry, and integrated care teams seeking measurable brain health outcomes.

Growth Signals Historical recognition as a fast-growing private company and ongoing government and defense interest (US Air Force engagement) suggest established credibility and potential for expanded clinical contracts and research collaborations with high-reliability customers.

Platform Synergy The transition to a scalable cognitive electrophysiology platform across behavioral health, neurology, integrative medicine, and research opens up cross-sell opportunities to clinics and research centers aiming to consolidate brain health assessments under a single workflow.

Financial Tailwinds With revenue in the small-to-mid single-digit millions and strong alignment with Firefly’s AI-driven brain health solutions, there is potential to upsell larger hospital systems, large group practices, and managed care networks focused on objective cognitive metrics and outcome tracking.